Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

5.94
-0.2200-3.57%
Post-market: 6.000.0600+1.01%18:05 EDT
Volume:653.00K
Turnover:3.92M
Market Cap:297.69M
PE:-1.29
High:6.31
Open:6.10
Low:5.91
Close:6.16
Loading ...

REGENXBIO Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

REGENXBIO Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
20 Mar

Regenxbio Shares up 5.6% on Early Data From Gene Therapy for Muscle Disorder

THOMSON REUTERS
·
20 Mar

BUZZ-Regenxbio rises on early data from gene therapy for muscle disorder

Reuters
·
19 Mar

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy

MT Newswires Live
·
19 Mar

Regenxbio Shares Rise After Positive Trial Data for RGX-202

Dow Jones
·
19 Mar

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

PR Newswire
·
19 Mar

Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley

TIPRANKS
·
18 Mar

Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink

TIPRANKS
·
18 Mar

RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
18 Mar

Q4 2024 Regenxbio Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

REGENXBIO Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
14 Mar

Stifel Nicolaus Keeps Their Buy Rating on RegenXBio (RGNX)

TIPRANKS
·
14 Mar

Regenxbio Inc : Morgan Stanley Raises Target Price to $24.00 From $22.00

THOMSON REUTERS
·
14 Mar

Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience

GuruFocus.com
·
14 Mar

REGENXBIO Reports Progress in Gene Therapy Pipeline

TIPRANKS
·
14 Mar

Regenxbio Q4 License & Royalty Revenue USD 21.214 Million

Reuters
·
14 Mar